Clinical safety of robenacoxib in cats with chronic musculoskeletal disease
| Autor: | Derek Adrian, Sophie Forster, Gabriele Friton, Wolfgang Seewald, B. Duncan X. Lascelles, Jonathan N. King |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Veterinary medicine adverse event Standard Article Placebo Cat Diseases chemistry.chemical_compound Internal medicine SF600-1100 medicine Animals Musculoskeletal Diseases Prospective Studies Adverse effect Phenylacetates Pharmacology General Veterinary Robenacoxib business.industry Anti-Inflammatory Agents Non-Steroidal Diphenylamine coxib medicine.disease Confidence interval Standard Articles NSAID Clinical trial chemistry Concomitant Relative risk Cats SMALL ANIMAL business Kidney disease harm |
| Zdroj: | Journal of Veterinary Internal Medicine Journal of Veterinary Internal Medicine, Vol 35, Iss 5, Pp 2384-2394 (2021) |
| ISSN: | 1939-1676 0891-6640 |
| Popis: | Background Evaluate the clinical safety of robenacoxib in cats with chronic musculoskeletal disease (CMSD). Animals Four hundred forty‐nine client‐owned cats with CMSD. Methods Pooled analysis of safety variables from 4 prospective randomized blinded clinical trials of robenacoxib (n = 222) versus placebo (n = 227), administered orally once daily for 4 to 12 weeks. Safety was evaluated from reported adverse events (AEs) and abnormalities detected on hematology and serum and urine chemistry analyses. Results The number of cats with at least 1 AE was not significantly different (P = .15) with robenacoxib (n = 106, 47.8%) compared to placebo (n = 93, 41.0%). The relative risk of at least 1 AE (incidence robenacoxib/placebo) was 1.15 (95% confidence interval 0.93‐1.43). There was no significant difference between groups in the number of clinical signs (range, 0‐9) per cat (P = .23). Serum creatinine concentrations were higher during robenacoxib administration compared to placebo (+4.36 μmol/L, 95% confidence interval 0.21‐8.50), but no related adverse clinical effects were detected. In the subgroup of 126 cats with evidence of chronic kidney disease, the relative risk of at least 1 AE (robenacoxib/placebo) was 1.09 (95% confidence interval 0.78‐1.52, P = .61). Conclusions and Clinical Importance Robenacoxib was not associated with increased risk of AEs compared to placebo when administered for 4 to 12 weeks to cats with CMSD. The generalizability of the results to general practice is limited by the fact that cases with severe and uncontrolled concomitant diseases were not included. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text